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Within the European community more than a million indi-
viduals develop cancer every year (Moller Jensen et al.,
1990). Of these cases, over 50% will be aged over 70 years
and this proportion will gradually increase as a result of
longevity since age is a major risk determinant for malig-
nancy. Despite the frequency of cancer in the elderly, treat-
ment has often been given on an ad hoc basis and very rarely
have structured management schemes been tested in prospec-
tive randomised trials. Undertreatment of cancer has been
rife, irrespective of tumour site and the discipline of the
clinician looking after the patient.
Who are the elderly?
No agreement exists as to the definition of the elderly, who
have been variously described as being aged from over 65
years to over 85 years. The majority of clinical trials have
excluded patients aged over 70 years so by default this can be
described as the oncological definition of old age. There has
also been a tacit assumption that the words elderly and frail
are synonymous. That this is not true is confirmed by a
recent general practice survey. In 1990, Hall et al. studied 775
registered patients aged more than 75 years and used Kings
Fund Categories to determine their dependence:
1. Fit and active.
2. Lifestyle disturbed appreciably, but not housebound.
3. Lifestyle severely disturbed and housebound.
4. Bedfast.
There were two males in category 4 and the remainder were
classified as one fit, two partially disabled, and three house-
bound. The distribution by age is shown in Table I. This
shows that over 90% of men aged between 75 and 84 were
mobile, as compared with 80% of women of the same age.
Even among those aged 85 years, 78% of males and 56% of
females were either fully fit or only partially disabled. Thus
the majority of the elderly are not suffering a restricted
lifestyle because of chronic disease.
At present, general practitioners in Britain are under pres-
sure to screen the elderly for treatable diseases. This does not
appear to extend to screening for cancer. Breast screening is
being offered to women aged 50-65, and those over 65 are
not being encouraged to attend. That there is extensive
unrecognised malignancy has been demonstrated in an autop-
sy study from Scandinavia. (Maartmann-Moe & Hartveit,
1990). From a total of 571 cases with pathologically
confirmed gastric carcinoma at autopsy, no clinical diagnosis
had been made in 165 (29%) and this was responsible for the
deaths of 62 (11%).
Surgery
Some would argue that a missed diagnosis of gastric car-
cinoma is of no consequence since the disease is usually
Table I Functional disability and age in general practice
Fit Partially disabled Housebound
75-79y
M 41 51 8
F 32 54 14
80-84y
M 31 58 10
F 20 58 22
>85y
M 25 53 22
F 11 44 44
Hall, 1990.
untreatable. This is not necessarily so. In specialised centres
excellent results can be achieved. Brandoh reported a series
of 292 patients with gastric carcinoma treated by total gas-
trectomy, of whom 60 (21%) were aged more than 70 years.
Pre-operative risk factors such as diabetes, hypertension, car-
diac and pulmonary dysfunction were present in 35% of
those aged less than 70 and in 90% of those in the elderly
group. Despite this, the operative mortality rate was only 3%
in the elderly group and 1% among younger patients. Post-
operative morbidity including anastomotic leaks, haemorr-
hage, and cardiac or pulmonary complications occurred in
24% of those aged less than 70 and 32% of the older group.
The 5 year survival after curative gastrectomy was 49% for
both younger and older patients. These data may be con-
trasted with those from a non-specialist centre in which
operations were carried out by surgeons in various stages of
training, (Herron et al., 1960). Under these circumstances the
operative mortality was 33%, and 62% of patients developed
postoperative complications.
Another example of the benefits of specialisation in surgery
is the Mayo Clinic experience with radical pancreatectomy
for carcinoma of the pancreas, (Spencer et al., 1990). Of a
series of 42 consecutive patients aged over 70 years subjected
to either radical, total or distal pancreatectomy the operative
mortality rate was 9%. Surgical complications occurred in
28% of cases and medical problems in 12%. It was conc-
luded that aggressive surgery should not be avoided on
grounds of age alone.
Radiotherapy
The treatment of many cancers has become multidisciplinary
with optimal results being achieved where there is close
cooperation between pathologist, surgeon, radiotherapist and
medical oncologist. However, this approach may not be
adopted in management of elderly patients. Chu et al.
examined various aspects of the impact of age on treatment
of cancer (Chu et al., 1987). Two indicators used were the
adoption of a multidisciplinary approach and the offer of
support groups. Table II shows a substantial reduction in
both among patients aged more than 75 years. Approx-
imately two thirds of younger patients were managed by a
multidisciplinary approach as compared with only one third
of those over 75 years.
One particular aspect of this is that some surgeons may
not refer their elderly patients for radiotherapy. After a wide
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Table II Effect of age on management of cancer
0-44 45-54 55-64 65-74 > 75
No. 190 251 411 373 332
Multidisciplinary 67 61 52 47 36
approach (%)
Support offer (%) 69 61 60 59 44
Chu, 1987.
local excision the NSABP B-06 trial demonstrated among
patients aged less than 70 years that without breast irradia-
tion a local relapse occurred in approximately one third of
cases. (Fisher et al., 1985). This was substantially reduced
among those who were irradiated.
In a non-randomised study, Kantorowitz et al., reported
that only 40% of patients aged over 60 years were referred
for post-operative irradiation after wide local excision, (Kan-
torowitz et al., 1988). Relapse of cancer within the breast
occurred in 40% of those who were not irradiated, compared
with only 6% of those given post-operative radiotherapy.
Chemotherapy
Several real and theoretical problems complicate the use of
chemotherapy in elderly patients. Firstly, some will have
undiagnosed pre-existing conditions leading to impairment of
myocardial or pulmonary function. Others will be receiving a
variety of drugs, and it has been suggested that interaction
may occur in up to 50% of cases. (Brown et al., 1977).
Compliance with treatment may not occur in up to one third,
and half may make errors in self-medication, (Schwartz et al.,
1962).
Both hepatic and renal function may be reduced as a result
of age changes and there may be a loss of up to one third of
the bone marrow stem cells thereby leading to potential
toxicity (Ouslander, 1981). Alteration in tissue cellularity and
fatty replacement may act together with reduced excretion of
drugs to amplify toxicity at target organs (Montamat, 1989).
There are a variety of approaches to this problem ofwhich
the least effective may be to introduce empirical reductions in
all the elderly irrespective of their functional capacity. An-
other approach is to tailor dose reduction to renal function
when using cytotoxics excreted by this route. Gelman et al.
proposed dose reduction of CMF for patients with advanced
breast cancer in relation to creatinine clearance, (Gelman &
Taylor, 1984). This achieved a significant reduction in tox-
icity but with a concomitant loss of efficacy.
A more logical plan may be to study the pharmacokinetics
of drug treatment in the elderly to attempt to achieve a
similar target area under the time/concentration curve to that
observed with younger patients (Monfardini, 1991). Appro-
priate alteration to dosage and timing may then allow an
equally effective treatment to be given. Such studies have not
yet been reported. For the elderly single drugs may be
preferable to combinations. Such patients may also be suit-
able for testing agents in phase I studies of novel agents
rather than using those presently used cases who have
relapsed after multiple prior therapies.
Breast cancer in the elderly
As the commonest solid tumour in females which can be
cured by surgery, with or without radiotherapy and/or drugs,
and a hormonally sensitive cancer the outlook for the elderly
with breast cancer should be good. That this is not so
becomes apparent when the literature is studied. Greenfield
reviewed the hospital notes of 420 patients attending seven
hospitals (Greenfield et al., 1987). Notes were rated on a
basis of diagnostic workshop, adequacy of staging, and
appropriateness of treatment. In addition co-morbidity was
graded.
1. No co-morbidity.
2. Mild controlled co-morbidity.
3. Moderate/severe co-morbidity.
Of patients aged 50-69, 17% were deemed to have had
inappropriate management as compared with 33% of those
aged over 70 years. Of those patients with Stage I/II breast
cancers and who had co-morbidity levels of 0/1, 4% of the
younger group were inappropriately managed compared with
17% of those aged over 70. The authors concluded that
patients with this highly treatable disease were managed ac-
cording to chronological age without regard to physiological
conditions and that this age bias may result in a less
favourable prognosis than could be achieved with currently
recommended therapy.
Yancik et al. analysed data derived from the NCI's
Surveillance, Epidemiology and End Result (SEER) prog-
ramme which included 125,000 women with breast cancer
(Yancik et al., 1989). Surgery was less likely to be performed
in those aged over 85, and in this group was less likely to be
extensive. When divided into stages and after adjusting for
non-cancer deaths there was no difference in the survival of
those with localised disease, irrespective of age.
The treatment of breast cancer has been both improved
and complicated by the advent of tamoxifen, a non-toxic
partial oestrogen antagonist. After being used extensively for
the treatment of advanced breast cancer and also as an
adjuvant after surgery for early disease, it was then used to
treat operable disease in the elderly. In the study with the
longest follow-up Horobin reported results on 113 patients
aged over 70 years given tamoxifen 20 mg twice daily (Horo-
bin et al., 1991). Progression of disease was observed
originally in 24 (21%). With a minimum follow-up of 5 years
progression occurred in a further 37 (33%). There were 16
(14%) alive without relapse and 26 (23%) who died without
progression. Thus overall, tamoxifen achieved long-term con-
trol in 42 (37%).
Various prospective randomised trials have been conducted
to examine the role of tamoxifen in the elderly, and each had
a different design, as shown in Table III (Gazet et al., 1988;
Robertson et al., 1988; Bates et al., 1991). With the exception
of the St Georges trial, which compared sub-optimal surgery
with tamoxifen, all the other studies have shown an increased
risk of relapse in the breast of those given tamoxifen. The
EORTC trials have not yet been analysed. A preliminary
analysis has been conducted of the Guy's Hospital compo-
nent of 10850. Of a total of 134 patients, 61 were treated by
modified radical mastectomy and 73 by tumourectomy and
Table In Trials of tamoxifen treatment for women aged >70 years
with operable breast cancer
Trial Treatment No. Follow up RFS OS
Tamoxifen 40 mg 60 75% 72%
St Georges < 36 months NWide excision or
mastectomy 56 62% 82%
Tamoxifen 40 mg 68 70% 85%
Nottingham< 24 months
Wedge mastectomy 67 75% 75%
Tamoxifen 20mg 183 72% 83%
CRC 34 months
Optimal surgery +
Tamoxifen 20 mg 171 86% 85%
Tumourectomy +
Tamoxifen 20 mg 112
EORTC/
10850 K
Modified radical
mastectomy 115
Tamoxifen 20 mg 78
EORTC /
10850 K
Modified radical
mastectomy 81TREATMENT OF CANCER IN THE ELDERLY 995
tamoxifen. After a median follow-up of 6 years relapse free
survival was 68% for the tamoxifen group and 80% for the
mastectomy group. Overall survival of the two groups was
similar (78% and 80%).
Thus these studies suggest that tamoxifen alone may
achieve long term control in less than 50% of patients, and
this may increase to two thirds of those treated by tumourec-
tomy and tamoxifen. There may be a subset who can be
treated by tamoxifen without risk of relapse but such cases
have not yet been identified. At present long-term follow-up
is necessary which may be difficult for some patients. Al-
though mastectomy achieves satisfactory long term control of
local disease, this may be unacceptable to many. A different
approach to this problem may be to use a combination of
surgery and radiotherapy, but give the entire radiation treat-
ment using an iridium or caesium implant, which would
enable the entire treatment to be given over 5 days (Fentiman
et al., 1991).
This type of approach would be applicable to anyone fit
enough for general anaesthesia. For the very frail, a hypo-
fractioned treatment given on three occasions on an out-
patient basis may be a more effective form of local control
than tamoxifen alone. Such approaches warrant testing in
clinical trials.
Conclusions
The attitudes of both patients and doctors have to be
changed in relation to the management of cancer in the
elderly. Entry criteria for clinical trials need to be broadened
so that age alone is not a barrier. For those patients who are
not entered into trials, their treatment should be the best
available. Criteria for frailty need to be agreed and specific
protocols designed for the improvement of treatment for
such individuals. The elderly are an appropriate group to
receive effective treatment and their inclusion in studies will
increase the chances of improving the results of both local
and systemic therapies.
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